Treatment of early Rheumatoid Arthritis with minocycline or placebo. Results of a Randomized, double‐blind, placebo‐controlled trial

Authors:
  • CHClaire E. Haire
    Claire E. Haire
  • WPWilliam Palmer
    William Palmer
  • WDWalter Drymalski
    Walter Drymalski
  • SWSteven Wees
    Steven Wees
  • KBKent Blakely
    Kent Blakely
  • MCMelvin Churchill
    Melvin Churchill
  • PEP. James Eckhoff
    P. James Eckhoff
  • AWArthur Weaver
    Arthur Weaver
  • DDDeborah Doud
    Deborah Doud
  • NENils Erikson
    Nils Erikson
  • FDFred Dietz
    Fred Dietz

Abstract
Objective. To determine if minocycline is an effective therapy for seropositive rheumatoid arthritis (RA) when used within the first year of disease.Methods. The Rheumatoid Arthritis Investigational Network enrolled 46 patients with RA of Results. Eighteen of the 46 patients who were enrolled met 50% improvement criteria at 3 months, and maintained at least a 50% improvement for 6 months with no significant drug toxicity. Among them were 15 of the 23 patients (65%) treated with minocycline and 3 of 23 patients (13%) treated with placebo (P < 0.001).Conclusion. In patients with early seropositive RA, therapy with minocycline is superior to placebo.

This publication has 40 references indexed in Scilit: